



BioCorporate profile downloaded from - <http://www.bioportfolio.com> on Friday, January 09, 2009

## Advanced Cell Technology Incorporated

[View the current Advanced Cell Technology Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/bi corporate/155-Advanced+Cell+Technology+Incorporated.html)

(<http://www.bioportfolio.com/bi corporate/155-Advanced+Cell+Technology+Incorporated.html>)

### Contact Details:

**1201 Harbor Bay Parkway Suite 120**  
**Alameda**

Tel: 310.481.5124

Fax: 510.748.4950

Email: [mwest@advancedcell.com](mailto:mwest@advancedcell.com)

**94502**

**United States of America**

Advanced Cell Technology Announces License of its Cloning Patents to Immerge Biotherapeutics, INC., a Joint Venture Between Novartis Pharma Ag and Biotransplant, Inc. Worcester, MA, April 16, 2002—Advanced Cell Technology, Inc. (ACT) announced today the license of animal cloning technology to Immerge BioTherapeutics, Inc. of Charlestown, MA. The worldwide nonexclusive license will cover Immerge's work in the development of genetically modified pigs for potential use in xenotransplantation (the use of animal organs to address human health issues). "We are excited to participate in a program that offers such hope for thousands of people," said Michael D. West, Ph.D., President and C.E.O. of ACT. "Xenotransplantation may one day offer life-saving technology for people with kidney, lung, and heart failure and other degenerative diseases." Immerge was formed as a joint venture between Novartis Pharma AG (NYSE:NVS) and BioTransplant, Incorporated (Nasdaq: BTRN) in September, 2000. Since that time, the company has reached two important milestones – the development of inbred miniature swine that are incapable of transmitting porcine retrovirus that can infect human cells and the development of the first knock-out cloned miniature swine. Both of these milestones have moved xenotransplantation closer to the clinic. Immerge has also previously announced a collaboration in pig nuclear transfer cloning with Infigen, Inc. "Cloning plays an important role in the further development of xenotransplantation and in the Immerge program," said Julia Greenstein, Ph.D. President and C.E.O. of Immerge. "ACT's technology will be an important enhancement to the intellectual property supporting our work." The patents licensed to Immerge include U.S. Patent Nos. 6,235,970, 6,235,969, 6,215,041, and 5,945,577, the latter being the subject of an interference proceeding with Geron Corporation. Immerge will have the right to contract with third parties to manufacture product using ACT's cloning technology. The need to find new sources for donor organs is a critical one, and the demand is growing each day. According to the United Network for Organ Sharing (UNOS), there are currently more than 79,000 people on the U.S. transplant waiting list and a new name is added to the list every 14 minutes. An equal number of prospective transplant patients never make the list because of the strict criteria needed to ensure that precious organs go to those candidates that are most likely to be successful recipients. Xenotransplantation offers the best hope for these people. Advanced Cell Technology is a biotechnology company focused on the discovery and commercialization of cloning technology for application in medicine and agriculture.

- [Hemangioblasts from human embryonic stem cells generate multilayered blood vessels with functional smooth muscle cells.](#)  
*BACKGROUND: The formation and regeneration of functional vasculatures...*25th December, 2008  
 Advanced Cell Technology, Worcester, Massachusetts, MA 01605, USA.- Regen Med. 2009 Jan;4(1):37-47. ([DOI Direct Link](#))
- [Robust generation of hemangioblastic progenitors from human embryonic stem cells.](#)  
*BACKGROUND: Human embryonic stem cells (hESCs) are a potentially...*15th November, 2008  
 Advanced Cell Technology, 381 Plantation Street, Worcester, MA 01605, USA.- Regen Med. 2008 Sep;3(5):693-704. ([DOI Direct Link](#))
- [Biologic properties and enucleation of red blood cells from human embryonic stem cells.](#)  
*Human erythropoiesis is a complex multistep process that involves the...*21st August, 2008  
 Advanced Cell Technology, Worcester, MA, USA.- Blood. 2008 Dec 1;112(12):4475-84. Epub 2008 Aug 19. ([DOI Direct Link](#))
- [GeneChip analysis of human embryonic stem cell differentiation into hemangioblasts: an in silico dissection of mixed phenotypes.](#)  
*BACKGROUND: Microarrays are being used to understand human embryonic stem...*9th August, 2008  
 Advanced Cell Technology,- Genome Biol. 2007;8(11):R240. ([DOI Direct Link](#))
- [Efficient differentiation of functional hepatocytes from human embryonic stem cells.](#)  
*Differentiation of human embryonic stem cells (hESCs) to specific...*29th July, 2008  
 Advanced Cell Technology, 381 Plantation Street, Worcester, Massachusetts- Stem Cells. 2008 May;26(5):1117-27. Epub 2008 Feb 21. ([DOI Direct Link](#))
- [Derive and conquer: sourcing and differentiating stem cells for therapeutic applications.](#)  
*Although great progress has been made in the isolation and culture of stem...*19th February, 2008  
 Advanced Cell Technology, 381 Plantation Street, Worcester, Massachusetts- Nat Rev Drug Discov. 2008 Feb;7(2):131-42. ([DOI Direct Link](#))
- [Recombinant HoxB4 fusion proteins enhance hematopoietic differentiation of human embryonic stem cells.](#)  
*Enforced expression of the HoxB4 gene promotes expansion of hematopoietic...*14th December, 2007  
 Advanced Cell Technology, Worcester, MA 01605, USA.- Stem Cells Dev. 2007 Aug;16(4):547-59. ([DOI Direct Link](#))
- [Derivation of human embryonic stem cells from single blastomeres.](#)  
*This protocol details a method to derive human embryonic stem (hES) cells...*7th December, 2007  
 Advanced Cell Technology, Worcester, Massachusetts 01605, USA.- Nat Protoc. 2007;2(8):1963-72. ([DOI Direct Link](#))
- [Advanced Cell Technology, Inc.](#)  
*Advanced Cell Technology, Inc. (OTCBB: ACTC) is a biotechnology company...*20th September, 2007  
 Advanced Cell Technology, Inc.- Regen Med. 2007 Mar;2(2):217-20. ([DOI Direct Link](#))
- [Cellular reprogramming.](#)  
*The concept of reprogramming a cell is very intriguing and has immense...*19th August, 2007  
 Molecular and Cell Biology, Advanced Cell Technology, Inc., Worcester,- Methods Enzymol. 2006;420:265-83. ([DOI Direct Link](#))
- [Generation of functional hemangioblasts from human embryonic stem cells.](#)  
*Recent evidence suggests the existence of progenitor cells in adult...*6th July, 2007  
 Advanced Cell Technology, Worcester, Massachusetts 01605, USA.- Nat Methods. 2007 Jun;4(6):501-9. Epub 2007 May 7. ([DOI Direct Link](#))
- [Hematopoietic cells from primate embryonic stem cells.](#)

*Embryonic stem (ES) cells, derived from early stage embryos, are...*31st January, 2007  
Advanced Cell Technology, Biotech Five, Worcester, Massachusetts, USA.- Methods Enzymol.  
2006;418:243-51. ([DOI Direct Link](#))

- [Retinal pigment epithelium.](#)

*Retinal pigment epithelium (RPE) arises from neuroectoderm and plays a key...*31st January, 2007  
Advanced Cell Technology, Worcester, Massachusetts, USA.- Methods Enzymol. 2006;418:169-94. ([DOI Direct Link](#))

- [Embryonic stem cells using nuclear transfer.](#)

*Despite the fact that embryonic stem (ES) cells are able to differentiate...*31st January, 2007  
Advanced Cell Technology, Biotech Five, Worcester, Massachusetts, USA.- Methods Enzymol.  
2006;418:135-47. ([DOI Direct Link](#))

- [Embryonic stem cells from single blastomeres.](#)

*The fact that deriving embryonic stem (ES) cells from a blastocyst...*31st January, 2007  
Advanced Cell Technology, Biotech Five, Worcester, Massachusetts, USA.- Methods Enzymol.  
2006;418:108-16. ([DOI Direct Link](#))

## BioNews Results for Advanced Cell Technology Incorporated



- [CHA Biotech, Advanced Cell JV to known as Stem Cell & Regenerative Medicine](#)

*Bio Spectrum Asia: Dec 31 2008 7:56AM Matching: advanced cell technology*

- [Joint Venture Between CHA Biotech and Advanced Cell Technology to be called EURStem Cell & Regenerative Medi](#)

*BioSpace: Dec 31 2008 12:39AM Matching: advanced cell technology*

- [Joint Venture Between CHA Biotech and Advanced Cell Technology to be called EURStem Cell & Regenerative Medi](#)

*Business Wire: Dec 30 2008 5:18PM Matching: advanced cell technology*

- [Joint Venture Between CHA Biotech and Advanced Cell Technology to be called Stem Cell & Regenerative Medi](#)

*Stockwatch: Dec 30 2008 5:34PM Matching: advanced cell technology*

- [Joint Venture Between CHA Biotech and Advanced Cell Technology to be called Stem Cell & Regenerative Medicine](#)

*Globe Investor: Dec 30 2008 5:27PM Matching: advanced cell technology*

- [Joint Venture Between CHA Biotech and Advanced Cell Technology to be called Stem Cell & Regenerative Medicine](#)

*Yahoo! Canada: Dec 30 2008 6:02PM Matching: advanced cell technology*

- [Joint Venture Between CHA Biotech and Advanced Cell Technology to be called 'Stem Cell & Regenerative Medicine](#)

*Forbes.com: Dec 30 2008 6:11PM Matching: advanced cell technology*

- [Joint Venture Between CHA Biotech and Advanced Cell Technology to be called 'Stem Cell & Regenerative Medicine](#)

*TradingMarkets: Dec 30 2008 5:48PM Matching: advanced cell technology*

- [Joint Venture Between CHA Biotech and Advanced Cell Technology to be called 'Stem Cell & Regenerative Medi](#)

*Street Insider: Dec 30 2008 5:30PM Matching: advanced cell technology*

- [Joint Venture Between CHA Biotech and Advanced Cell Technology to be called 'Stem Cell & Regenerative Medicine](#)

*MarketWatch: Dec 30 2008 5:26PM Matching: advanced cell technology*

- [Joint Venture Between CHA Biotech and Advanced Cell Technology to be called EURStem Cell &](#)

## [Regenerative Medi](#)

*Genetic Engineering News: Dec 30 2008 5:58PM Matching: advanced cell technology*

- [ACT, CHA joint venture gets a new, lengthy name](#)

*Mass High Tech: Dec 30 2008 7:06PM Matching: advanced cell technology*

- [Joint Venture Between CHA Biotech and Advanced Cell Technology to](#)

*Business Wire via MSN Money: Dec 30 2008 5:37PM Matching: advanced cell technology*

- [Joint Venture Between CHA Biotech and Advanced Cell Technology to be called Stem Cell & Regenerative Medicine](#)

*Business Wire via Yahoo!: Dec 30 2008 5:20PM Matching: advanced cell technology*

- [Joint Venture Between CHA Biotech and Advanced Cell Technology to be called EURStem Cell & Regenerative Medi](#)

*Pharma Live: Dec 30 2008 7:44PM Matching: advanced cell technology*

## **BioCorporate Profiles - upgrade to a full profile**

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10  
Copyright 1997-2008 - BioPortfolio Limited.

